Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® - Evoke Pharma ( NASDAQ:EVOK )

2 weeks ago

Analysis of real-world data compared patients on GIMOTI ( n=51 ) to Oral Metoclopramide ( n=41 ) , both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits ( -91%, p=0.001 ) , All Cause Office Visits ( -41%, ...

Ticker	Sentiment	Impact
EVOK	Neutral	12 %